|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Annexin A2 as a biomarker for hepatocellular carcinoma in Egyptian patients显示文摘AIM To investigate the clinical utility of serum annexin A2(ANXA2) as a diagnostic marker for early hepatocellular carcinoma(HCC).METHODS This study was performed in HCC Clinic of Ain Shams University Hospitals, Cairo, Egypt and included: Group 1: Fifty patients with early stage HCC(Barcelona Clinic Liver Cancer stage A); Group 2: Twenty five patients with chronic liver disease; and Control Group: Fifteen healthy, age-and sex-matched subjects who were seronegative for viral hepatitis markers. The followinglaboratory investigations were done: Viral hepatitis markers [hepatitis B surface antigen and hepatitis C virus(HCV) antibodies], HCV RNA in HCV antibody-positive patients, serum alpha fetoprotein(AFP), and serum ANXA2 levels.RESULTS In this study, 88% of HCC patients(n = 44) were HCVpositive, while HBV infection represented only 8% of all HCC patients(n = 4); and two patients were negative for both viral markers. A highly significant difference was found between patients with HCC and chronic liver disease as well as controls with regard to serum ANXA2 levels(130, IQR 15-240; 15, IQR 15-17; and 17, IQR 15-30 ng/m L, respectively). The area under the curve of ANXA2 was 0.865; the cut-off value was established to be 18 ng/mL with a diagnostic sensitivity of 74% and a specificity of 88%, while the sensitivity and specificity of AFP at the cut-off value of 200 ng/dL were 20% and 100%, respectively.CONCLUSION Serum ANXA2 may serve as a biomarker for the early detection of HCC. | Mohamed K Shaker Hanzada I Abdel Fattah Ghada S Sabbour Iman F Montasser Sara M Abdelhakam Eman El Hadidy Rehab Yousry Ahmed K El Dorry | 2017 | World Journal of Hepatology2017，9，9： | 4 |
| 2 | Occult hepatitis B virus infection among Egyptian blood donors显示文摘AIM:To identify blood donors with occult hepatitis B virus(HBV) infection(OBI) to promote safe blood donation.METHODS:Descriptive cross sectional study was conducted on 3167 blood donors negative for hepatitis B surface antigen(HBsAg),hepatitis C antibody(HCV Ab) and human immunodeficiency virus Ab.They were subjected to the detection of alanine aminotransferase(ALT) and aspartate transaminase(AST) and screening for anti-HBV core antibodies(total) by two different techniques;[Monoliza antibodies to hepatitis B core(Anti-HBc) Plus-Bio-Rad] and(ARC-HBc total-ABBOT).Positive samples were subjected to quantitative detection of antibodies to hepatitis B surface(anti-HBs)(ETI-AB-AUK-3,Dia Sorin-Italy).Serum anti-HBs titers > 10 IU/L was considered positive.Quantitative HBV DNA by real time polymerase chain reaction(PCR)(QIAGEN-Germany) with 3.8 IU/mL detection limit was estimated for blood units with negative serum anti-HBs and also for 32 whose anti-HBs serum titers were > 1000 IU/L.Also,265 recipients were included,34 of whom were followed up for 3-6 mo.Recipients were investigated for ALT and AST,HBV serological markers:HBsAg(ETI-MAK-4,Dia Sorin-Italy),anti-HBc,quantitative detection of anti-HBs and HBV-DNA.RESULTS:525/3167(16.6%) of blood units were positive for total anti-HBc,64% of those were antiHBs positive.Confirmation by ARCHITECT anti-HBc assay were carried out for 498/525 anti-HBc positive samples,where 451(90.6%) confirmed positive.Reactivity for anti-HBc was considered confirmed only if two positive results were obtained for each sample,giving an overall prevalence of 451/3167(14.2%) for total anti-HBc.HBV DNA was quantified by real time PCR in 52/303(17.2%) of anti-HBc positive blood donors(viral load range:5 to 3.5 x 105 IU/mL) with a median of 200 IU/mL(mean:1.8 x 104 ± 5.1 x 104 IU/mL).AntiHBc was the only marker in 68.6% of donors.Univariate and multivariate logistic analysis for identifying risk factors associated with anti-HBc and HBV-DNA positivity among blood donors showed that age above thirty and marriage were the most significant risk factors for prediction of anti-HBc positivity with AOR 1.8(1.4-2.4) and 1.4(1.0-1.9) respectively.Other risk factors as gender,history of blood transfusion,diabetes mellitus,frequent injections,tattooing,previous surgery,hospitalization,Bilharziasis or positive family history of HBV or HCV infections were not found to be associated with positive anti-HBc antibodies.Among anti-HBc positive blood donors,age below thirty was the most significant risk factor for prediction of HBV-DNA positivity with AOR 3.8(1.8-7.9).According to HBV-DNA concentration,positive samples were divided in two groups;group one with HBV-DNA ≥ 200 IU/mL(n = 27) and group two with HBV-DNA < 200 IU/mL(n = 26).No significant difference was detected between both groups as regards mean age,gender,liver enzymes or HBV markers.Serological profiles of all followed up blood recipients showed that,all were negative for the studied HBV markers.Also,HBV DNA was not detected among studied recipients,none developed post-transfusion hepatitis(PTH) and the clinical outcome was good.CONCLUSION:OBI is prevalent among blood donors.Nucleic acid amplification/HBV anti core screening should be considered for high risk recipients to eliminate risk of unsafe blood donation. | Zeinab N Said Manal H El Sayed Iman I Salama Enas K Aboel-Magd Magda H Mahmoud Maged El Setouhy Faten Mouftah Manal B Azzab Heidi Goubran Amal Bassili Gamal E Esmat | 2013 | World Journal of Hepatology2013，5，2： | 4 |
| 3 | Effectiveness of hepatitis B virus vaccination program in Egypt:Multicenter national project显示文摘AIM:To assess the effectiveness of hepatitis B virus(HBV) vaccination program among fully vaccinated children.METHODS:A national community based crosssectional study was carried out in 6 governorates representing Egypt. A total of 3600 children aged from 9 mo to 16 years who were fully vaccinated with HBV vaccine during infancy were recruited. Face to face interviews were carried out and sera were evaluated for hepatitis B surface antigen(HBsA g),anti-HBV core antibodies(total) and quantitative detection of hepatitis B surface antibody using enzyme linked immunoassays techniques. Samples positive to HBs Ag/anti-HBV core antibodies were subjected to quantitative HBV-DNA detection by real time polymerase chain reaction with 3.8 IU/L detection limit. RESULTS:Sero-protection was detected among 2059 children(57.2%) with geometric mean titers 75.4 ± 3.6 IU/L compared to 3.1 ± 2.1 IU/L among nonseroprotected children. Multivariate logistic analysis revealed that older age and female gender were the significant predicting variables for having non seroprotective level,with adjusted odds ratio 3.3,9.1and 14.2 among children aged 5 to < 10,10 to < 15 and ≥ 15 years respectively compared to those < 5 years and 1.1 among girls compared to boys with P < 0.01. HBs Ag was positive in 0.11% and breakthrough infection was 0.36% and 0.39% depending on positivity of anti-HBc and DNA detection respectively. The prevalence of HBV infection was significantly higher among children aged ≥ 7 years(0.59%) compared to 0.07% among younger children with odds ratio equal to 8.4(95%CI:1.1-64.2) and P < 0.01.The prevalence was higher among girls(0.48%) than boys(0.29%) with P > 0.05. C ON C LU S I ON :T he E gy pt ian c ompuls or y H B V vaccination program provides adequate protection. Occult HBV infection exists among apparently healthy vaccinated children. Adherence to infection control measures is mandatory. | Iman I Salama Samia M Sami Zeinab Nabil Ahmed Said Manal H El-Sayed Lobna A El Etreby Thanaa M Rabah Dalia M Elmosalami Amany T Abdel Hamid Somaia I Salama Aida M Abdel Mohsen Hanaa M Emam Safaa M Elserougy Amal I Hassanain Naglaa F Abd Alhalim Fatma A Shaaban Samia A Hemeda Nihad A Ibrahim Ammal M Metwally | 2015 | World Journal of Hepatology2015，7，22： | 2 |
| 4 | The Anatomy of the Grid:Enabling Scalable Virtual Organizations显示文摘 | FOSTER I IMAN C TUECKE1 S | 2001 | International Journal Supercomputer Applications2001，15，3： | 1 |
| 5 | An optimal scheme for fast rate fault detection based on multirate sampled data显示文摘 | IMAN I ZHAO Q CHEN T W | 2005 | Journal of Process Control2005，15，3： | 1 |
| 6 | Involvement of 1L-23 in en- teropathic arthritis patients with inflammatory bowel disease: prelimi- nary results显示文摘 | Tamer A Gheita Iman I Kenawy | 2014 | Clinical Rheumatology2014，33，： | 1 |
| 7 | An H∞ approach to fast rate fault rate fault detection for multirate sampled-data systems显示文摘 | IMAN I ZHAO Q CHEN T W | 2006 | Journal of Process Control2006，16，6： | 1 |
| 8 | Development of an On-line Rotor Crack Detection and Monitoring Sys- tem 显示文摘 | Iman I Scheibel J Azzaro S H | 1999 | Journal of Vibration Acoustics Stress and Reliability in Design1999，111，3： | 1 |
| 9 | Norm invariant discretization for sampled-data fault detection显示文摘 | IMAN I CHEN T ZHAO Q | 2005 | Automatica2005，41，9： | 1 |
| 10 | Development of an on-line ro- tor crack detection and monitoring system 显示文摘 | IMAN I SCHEIBEL J Azzaro S H | 1999 | Journal of Vibra- tion Acoustics Stress and Rehability in Design1999，111，3： | 1 |
| 11 | ,Improvement of dissolution properties of Carbamazepine through application of the liquisolid tablet technique显示文摘 | Saadia Tayel A Iman Soliman I Dina L | 2008 | Eur J Pharm Biopharm2008，69，1： | 1 |
| 12 | Design of a multiplex PCR method for detection of toxigenic-pathogenic in vibrio cholera显示文摘 | IMANI F A A IMAN I D HOSSEINI D R | 2013 | Asian Pacific Journal of Trc^rical Medicine2013，6，2： | 1 |
| 13 | The anatomy of the grid:enabling scalable virtual organizations显示文摘 | FOSTER I IMAN C TUECHE S | 2001 | International Journal of Supercomputer Applications2001，15，3： | 1 |
| 14 | Structure-properties relationship in cross-linked high-amvlose starch for use in controlled drug release显示文摘 | Pompilia I S Francois R Iman H | 2000 | Carbohydrate Research2000，，3： | 1 |
| 15 | The Anatomy of the Grid: Enabling Scalable Virtual Organizations显示文摘 | FOSTER I IMAN C TUECKE S | 2001 | International Journal of Supercomputer Applications2001，15，3： | 1 |
| 16 | An optimal scheme for fast rate fault detection based on multirate sampled data显示文摘 | Iman I Zhao Q Chen T W | 2005 | Journal of Process Control2005，15，3： | 1 |
| 17 | Inhibitory effect of( + )- catechin on the growth of influenza A,/PR/8 virus in MDCK cells 显示文摘 | Mantani N Iman N I Kawamata H | 2001 | Planta Med2001，67，3： | 1 |
| 18 | Impact of direct-acting antiviral regimens on hepatic and extrahepatic manifestations of hepatitis C virus infection显示文摘Hepatitis C virus(HCV)is a common cause of liver disease and is associated with various extrahepatic manifestations(EHMs).This mini-review outlines the currently available treatments for HCV infection and their prognostic effect on hepatic manifestations and EHMs.Direct-acting antiviral(DAA)regimens are considered pan-genotypic as they achieve a sustained virological response(SVR)>85%after 12 wk through all the major HCV genotypes,with high percentages of SVR even in advanced fibrosis and cirrhosis.The risk factors for DAA failure include old males,cirrhosis,and the presence of resistance-associated substitutions(RAS)in the region targeted by the received DAAs.The effectiveness of DAA regimens is reduced in HCV genotype 3 with baseline RAS like A30K,Y93H,and P53del.Moreover,the European Association for the Study of the Liver recommended the identification of baseline RAS for HCV genotype 1a.The higher rate of hepatocellular carcinoma(HCC)after DAA therapy may be related to the fact that DAA regimens are offered to patients with advanced liver fibrosis and cirrhosis,where interferon was contraindicated to those patients.The change in the growth of pre-existing subclinical,undetectable HCC upon DAA treatment might be also a cause.Furthermore,after DAA therapy,the T cell-dependent immune response is much weaker upon HCV clearance,and the down-regulation of TNF-αor the elevated neutrophil to lymphocyte ratio might increase the risk of HCC.DAAs can result in reactivation of hepatitis B virus(HBV)in HCV coinfected patients.DAAs are effective in treating HCV-associated mixed cryoglobulinemia,with clinical and immunological responses,and have rapid and high effectiveness in thrombocytopenia.DAAs improve insulin resistance in 90%of patients,increase glomerular filtration rate,and decrease proteinuria,hematuria and articular manifestations.HCV clearance by DAAs allows a significant improvement in atherosclerosis and metabolic and immunological conditions,with a reduction of major cardiovascular events.They also improve physical function,fatigue,cognitive impairment,and quality of life.Early therapeutic approach with DAAs is recommended as it cure many of the EHMs that are still in a reversible stage and can prevent others that can develop due to delayed treatment. | Iman Ibrahim Salama Hala M Raslan Ghada A Abdel-Latif Somaia I Salama Samia M Sami Fatma A Shaaban Aida M Abdelmohsen Walaa A Fouad | 2022 | World Journal of Hepatology2022，14，6： | 0 |
| 19 | Current and novel modalities for management of chronic hepatitis B infection显示文摘Over 296 million people are estimated to have chronic hepatitis B viral infection(CHB),and it poses unique challenges for elimination.CHB is the result of hepatitis B virus(HBV)-specific immune tolerance and the presence of covalently closed circular DNA as mini chromosome inside the nucleus and the integrated HBV.Serum hepatitis B core-related antigen is the best surrogate marker for intrahepatic covalently closed circular DNA.Functional HBV“cure”is the durable loss of hepatitis B surface antigen(HBsAg),with or without HBsAg seroconversion and undetectable serum HBV DNA after completing a course of treatment.The currently approved therapies are nucleos(t)ide analogues,interferon-alpha,and pegylated-interferon.With these therapies,functional cure can be achieved in<10%of CHB patients.Any variation to HBV or the host immune system that disrupts the interaction between them can lead to reactivation of HBV.Novel therapies may allow efficient control of CHB.They include direct acting antivirals and immunomodulators.Reduction of the viral antigen load is a crucial factor for success of immune-based therapies.Immunomodulatory therapy may lead to modulation of the host immune system.It may enhance/restore innate immunity against HBV(as toll-like-receptors and cytosolic retinoic acid inducible geneⅠagonist).Others may induce adaptive immunity as checkpoint inhibitors,therapeutic HBV vaccines including protein(HBsAg/pre S and hepatitis B core antigen),monoclonal or bispecific antibodies and genetically engineered T cells to generate chimeric antigen receptor-T or T-cell receptor-T cells and HBV-specific T cells to restore T cell function to efficiently clear HBV.Combined therapy may successfully overcome immune tolerance and lead to HBV control and cure.Immunotherapeutic approaches carry the risk of overshooting immune responses causing uncontrolled liver damage.The safety of any new curative therapies should be measured in relation to the excellent safety of currently approved nucleos(t)ide analogues.Development of novel antiviral and immune modulatory therapies should be associated with new diagnostic assays used to evaluate the effectiveness or to predict response. | Iman Ibrahim Salama Samia M Sami Somaia I Salama Ghada A Abdel-Latif Fatma A Shaaban Walaa A Fouad Aida M Abdelmohsen Hala M Raslan | 2023 | World Journal of Hepatology2023，15，5： | 0 |
您所在的机构暂未开通此部分的功能，请联系管理员